<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39351240</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1392898</StartPage><MedlinePgn>1392898</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1392898</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1392898</ELocationID><Abstract><AbstractText>In the recent history of the SARS-CoV-2 outbreak, vaccines have been a crucial public health tool, playing a significant role in effectively preventing infections. However, improving the efficacy while minimizing side effects remains a major challenge. In recent years, there has been growing interest in nanoparticle-based delivery systems aimed at improving antigen delivery efficiency and immunogenicity. Among these, self-assembled nanoparticles with varying sizes, shapes, and surface properties have garnered considerable attention. This paper reviews the latest advancements in the design and development of SARS-CoV-2 vaccines utilizing self-assembled materials, highlighting their advantages in delivering viral immunogens. In addition, we briefly discuss strategies for designing a broad-spectrum universal vaccine, which provides insights and ideas for dealing with possible future infectious sarbecoviruses.</AbstractText><CopyrightInformation>Copyright © 2024 Yang, Zeng, Wu, Li and Guo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kaiwen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Youqin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jinlin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097007">Nanovaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="N">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097007" MajorTopicYN="N">Nanovaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">VLP</Keyword><Keyword MajorTopicYN="N">ferritin</Keyword><Keyword MajorTopicYN="N">self-assembled nanoparticle</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351240</ArticleId><ArticleId IdType="pmc">PMC11440195</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1392898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chavda VP, Ghali E, Balar PC, Chauhan SC, Tiwari N, Shukla S, et al. . Protein subunit vaccines: Promising frontiers against COVID-19. J Control Release. (2024) 366:761–82. doi: 10.1016/j.jconrel.2024.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2024.01.017</ArticleId><ArticleId IdType="pubmed">38219913</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, et al. . COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. (2022) 7:146. doi: 10.1038/s41392-022-00996-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00996-y</ArticleId><ArticleId IdType="pmc">PMC9062866</ArticleId><ArticleId IdType="pubmed">35504917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. (2021) 27:205–11. doi: 10.1038/s41591-021-01230-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01230-y</ArticleId><ArticleId IdType="pubmed">33469205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. Bmj. (2021) 372:n296. doi: 10.1136/bmj.n296</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n296</ArticleId><ArticleId IdType="pubmed">33526412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. . Safety and efficacy of single-dose ad26.COV2.S vaccine against covid-19. N Engl J Med. (2021) 384:2187–201. doi: 10.1056/NEJMoa2101544</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Sastre A, Mena I. Novel vaccine strategies against emerging viruses. Curr Opin Virol. (2013) 3:210–6. doi: 10.1016/j.coviro.2013.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2013.02.001</ArticleId><ArticleId IdType="pmc">PMC3644304</ArticleId><ArticleId IdType="pubmed">23477832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum Vaccin Immunother. (2014) 10:2875–84. doi: 10.4161/hv.29594</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29594</ArticleId><ArticleId IdType="pmc">PMC5443060</ArticleId><ArticleId IdType="pubmed">25483662</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu MN, Kelly HG, Kent SJ, Wheatley AK. Current and future nanoparticle vaccines for COVID-19. EBioMedicine. (2021) 74:103699. doi: 10.1016/j.ebiom.2021.103699</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103699</ArticleId><ArticleId IdType="pmc">PMC8602808</ArticleId><ArticleId IdType="pubmed">34801965</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. . Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. (2022) 7:94. doi: 10.1038/s41392-022-00950-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00950-y</ArticleId><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. (2021) 385:1761–73. doi: 10.1056/NEJMoa2110345</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mRNA-1273 SARS-coV-2 vaccine. N Engl J Med. (2021) 384:403–16. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. (2021) 110:997–1001. doi: 10.1016/j.xphs.2020.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.12.006</ArticleId><ArticleId IdType="pmc">PMC7834447</ArticleId><ArticleId IdType="pubmed">33321139</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen B, Tolia NH. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines. (2021) 6:70. doi: 10.1038/s41541-021-00330-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00330-7</ArticleId><ArticleId IdType="pmc">PMC8119681</ArticleId><ArticleId IdType="pubmed">33986287</ArticleId></ArticleIdList></Reference><Reference><Citation>Machhi J, Shahjin F, Das S, Patel M, Abdelmoaty MM, Cohen JD, et al. . Nanocarrier vaccines for SARS-coV-2. Adv Drug Delivery Rev. (2021) 171:215–39. doi: 10.1016/j.addr.2021.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.01.002</ArticleId><ArticleId IdType="pmc">PMC7794055</ArticleId><ArticleId IdType="pubmed">33428995</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine DJ, Read BJ. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles. Curr Opin Immunol. (2020) 65:1–6. doi: 10.1016/j.coi.2020.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2020.01.007</ArticleId><ArticleId IdType="pmc">PMC7501207</ArticleId><ArticleId IdType="pubmed">32200132</ArticleId></ArticleIdList></Reference><Reference><Citation>Coolen AL, Lacroix C, Mercier-Gouy P, Delaune E, Monge C, Exposito JY, et al. . Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials. (2019) 195:23–37. doi: 10.1016/j.biomaterials.2018.12.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.12.019</ArticleId><ArticleId IdType="pubmed">30610991</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu MN, Pilkington EH, Lee WS, Tan HX, Davis TP, Truong NP, et al. . Engineered ferritin nanoparticle vaccines enable rapid screening of antibody functionalization to boost immune responses. Adv Healthc Mater. (2023) 12:e2202595. doi: 10.1002/adhm.202202595</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202202595</ArticleId><ArticleId IdType="pubmed">36786027</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitesides GM, Grzybowski B. Self-assembly at all scales. Science. (2002) 295:2418–21. doi: 10.1126/science.1070821</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1070821</ArticleId><ArticleId IdType="pubmed">11923529</ArticleId></ArticleIdList></Reference><Reference><Citation>Negahdaripour M, Golkar N, Hajighahramani N, Kianpour S, Nezafat N, Ghasemi Y. Harnessing self-assembled peptide nanoparticles in epitope vaccine design. Biotechnol Adv. (2017) 35:575–96. doi: 10.1016/j.biotechadv.2017.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2017.05.002</ArticleId><ArticleId IdType="pmc">PMC7127164</ArticleId><ArticleId IdType="pubmed">28522213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung HD, Kim N, Lee Y, Lee EJ. Protein-based nanoparticle vaccines for SARS-coV-2. Int J Mol Sci. (2021) 22:13445. doi: 10.3390/ijms222413445</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222413445</ArticleId><ArticleId IdType="pmc">PMC8703262</ArticleId><ArticleId IdType="pubmed">34948241</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. N Biotechnol. (2017) 39:174–80. doi: 10.1016/j.nbt.2017.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2017.07.010</ArticleId><ArticleId IdType="pmc">PMC7102714</ArticleId><ArticleId IdType="pubmed">28778817</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, Arora K, Roy SS, Joseph A, Rastogi R, Arora NM, et al. . Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front Immunol. (2023) 14:1123805. doi: 10.3389/fimmu.2023.1123805</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1123805</ArticleId><ArticleId IdType="pmc">PMC9947793</ArticleId><ArticleId IdType="pubmed">36845125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YI, Kim D, Yu KM, Seo HD, Lee SA, Casel MAB, et al. . Development of spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-coV-2 infection in ferrets. mBio. (2021) 12:e00230–21. doi: 10.1128/mBio.00230-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00230-21</ArticleId><ArticleId IdType="pmc">PMC8092224</ArticleId><ArticleId IdType="pubmed">33653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chroboczek J, Szurgot I, Szolajska E. Virus-like particles as vaccine. Acta Biochim Polonica. (2014) 61:531–9. doi: 10.18388/abp.2014_1875</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2014_1875</ArticleId><ArticleId IdType="pubmed">25273564</ArticleId></ArticleIdList></Reference><Reference><Citation>Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J, Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol. (2008) 380:252–63. doi: 10.1016/j.jmb.2008.04.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2008.04.049</ArticleId><ArticleId IdType="pmc">PMC2481506</ArticleId><ArticleId IdType="pubmed">18508079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba S, Frey SJ, Halfmann PJ, Kuroda M, Maemura T, Yang JE, et al. . Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Commun Biol. (2021) 4:597. doi: 10.1038/s42003-021-02128-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02128-8</ArticleId><ArticleId IdType="pmc">PMC8134492</ArticleId><ArticleId IdType="pubmed">34011948</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JFC, Peyret H, Saunders K, Castells-Graells R, Marsian J, Meshcheriakova Y, et al. . Synthetic plant virology for nanobiotechnology and nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. (2017) 9:e1447. doi: 10.1002/wnan.1447</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1447</ArticleId><ArticleId IdType="pmc">PMC5484280</ArticleId><ArticleId IdType="pubmed">28078770</ArticleId></ArticleIdList></Reference><Reference><Citation>Royal JM, Simpson CA, McCormick AA, Phillips A, Hume S, Morton J, et al. . Development of a SARS-coV-2 vaccine candidate using plant-based manufacturing and a tobacco mosaic virus-like nano-particle. Vaccines (Basel). (2021) 9:1347. doi: 10.3390/vaccines9111347</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111347</ArticleId><ArticleId IdType="pmc">PMC8619098</ArticleId><ArticleId IdType="pubmed">34835278</ArticleId></ArticleIdList></Reference><Reference><Citation>Carignan D, Herblot S, Laliberté-Gagné M-È, Bolduc M, Duval M, Savard P, et al. . Activation of innate immunity in primary human cells using a plant virus derived nanoparticle TLR7/8 agonist. Nanomedicine: Nanotechnology Biol Med. (2018) 14:2317–27. doi: 10.1016/j.nano.2017.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2017.10.015</ArticleId><ArticleId IdType="pubmed">29128662</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera-Ugarte SM, Bolduc M, Laliberté-Gagné M, Blanchette LJ, Garneau C, Fillion M, et al. . A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. Nanomedicine. (2022) 44:102584. doi: 10.1016/j.nano.2022.102584</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2022.102584</ArticleId><ArticleId IdType="pmc">PMC9287509</ArticleId><ArticleId IdType="pubmed">35850421</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha L, Chang X, Zhao H, Mohsen MO, Hong L, Zhou Y, et al. . Development of a vaccine against SARS-coV-2 based on the receptor-binding domain displayed on virus-like particles. Vaccines (Basel). (2021) 9:395. doi: 10.3390/vaccines9040395</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9040395</ArticleId><ArticleId IdType="pmc">PMC8073353</ArticleId><ArticleId IdType="pubmed">33923573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsen MO, Balke I, Zinkhan S, Zeltina V, Liu X, Chang X, et al. . A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. Allergy. (2022) 77:243–57. doi: 10.1111/all.15080</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15080</ArticleId><ArticleId IdType="pmc">PMC8653185</ArticleId><ArticleId IdType="pubmed">34496033</ArticleId></ArticleIdList></Reference><Reference><Citation>He D, Marles-Wright J. Ferritin family proteins and their use in bionanotechnology. N Biotechnol. (2015) 32:651–7. doi: 10.1016/j.nbt.2014.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2014.12.006</ArticleId><ArticleId IdType="pmc">PMC4571993</ArticleId><ArticleId IdType="pubmed">25573765</ArticleId></ArticleIdList></Reference><Reference><Citation>Olshefsky A, Richardson C, Pun SH, King NP. Engineering self-assembling protein nanoparticles for therapeutic delivery. Bioconjug Chem. (2022) 33:2018–34. doi: 10.1021/acs.bioconjchem.2c00030</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.2c00030</ArticleId><ArticleId IdType="pmc">PMC9673152</ArticleId><ArticleId IdType="pubmed">35487503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, et al. . Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-coV-2 elicit robust protective immune responses. Immunity. (2020) 53:1315–30.e9. doi: 10.1016/j.immuni.2020.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.015</ArticleId><ArticleId IdType="pmc">PMC7687490</ArticleId><ArticleId IdType="pubmed">33275896</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce MG, King HAD, Elakhal-Naouar I, Ahmed A, Peachman KK, Macedo Cincotta C, et al. . A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci Transl Med. (2022) 14:eabi5735. doi: 10.1126/scitranslmed.abi5735</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi5735</ArticleId><ArticleId IdType="pubmed">34914540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W, Chai B, Feng S, Zhuang X, Ma J, Pang M, et al. . Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. Signal Transduct Target Ther. (2022) 7:173. doi: 10.1038/s41392-022-01041-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01041-8</ArticleId><ArticleId IdType="pmc">PMC9157036</ArticleId><ArticleId IdType="pubmed">35650183</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu M, Torres JL, Li Y, Van Ry A, Greenhouse J, Wallace S, et al. . One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. Emerg Microbes Infect. (2021) 10:2016–29. doi: 10.1080/22221751.2021.1994354</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1994354</ArticleId><ArticleId IdType="pmc">PMC8567933</ArticleId><ArticleId IdType="pubmed">34651563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, et al. . SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. Lancet Microbe. (2024) 5:e581–e93. doi: 10.1016/S2666-5247(23)00410-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00410-X</ArticleId><ArticleId IdType="pmc">PMC11192176</ArticleId><ArticleId IdType="pubmed">38761816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Li W, Rong H, Pan J, Zhang X, Hu Q, et al. . A nanoparticle vaccine displaying conserved epitopes of the preexisting neutralizing antibody confers broad protection against SARS-coV-2 variants. ACS Nano. (2024) 18:17749–63. doi: 10.1021/acsnano.4c03075</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.4c03075</ArticleId><ArticleId IdType="pubmed">38935412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sun J, Zheng J, Li S, Rao H, Dai J, et al. . Mosaic RBD nanoparticles elicit protective immunity against multiple human coronaviruses in animal models. Adv Sci (Weinh). (2024) 11:e2303366. doi: 10.1002/advs.202303366</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202303366</ArticleId><ArticleId IdType="pmc">PMC10916629</ArticleId><ArticleId IdType="pubmed">38105421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun TUJ, Andersson AC, Draper SJ, Howarth M. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano. (2018) 12:8855–66. doi: 10.1021/acsnano.8b02805</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b02805</ArticleId><ArticleId IdType="pmc">PMC6158681</ArticleId><ArticleId IdType="pubmed">30028591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale JB, Gonen S, Liu Y, Sheffler W, Ellis D, Thomas C, et al. . Accurate design of megadalton-scale two-component icosahedral protein complexes. Science. (2016) 353:389–94. doi: 10.1126/science.aaf8818</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8818</ArticleId><ArticleId IdType="pmc">PMC5485857</ArticleId><ArticleId IdType="pubmed">27463675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia Y, Bale JB, Gonen S, Shi D, Sheffler W, Fong KK, et al. . Design of a hyperstable 60-subunit protein dodecahedron. Nature. (2016) 535:136–9. doi: 10.1038/nature18010</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18010</ArticleId><ArticleId IdType="pmc">PMC4945409</ArticleId><ArticleId IdType="pubmed">27309817</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan TK, Rijal P, Rahikainen R, Keeble AH, Schimanski L, Hussain S, et al. . A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. (2021) 12:542. doi: 10.1038/s41467-020-20654-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20654-7</ArticleId><ArticleId IdType="pmc">PMC7822889</ArticleId><ArticleId IdType="pubmed">33483491</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel DR, Minns AM, Sim DG, Field CJ, Kerr AE, Heinly TA, et al. . Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model. Microbiol Spectr. (2024) 12:e0499822. doi: 10.1128/spectrum.04998-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.04998-22</ArticleId><ArticleId IdType="pmc">PMC10923206</ArticleId><ArticleId IdType="pubmed">38334387</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, et al. . Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-coV-2. Cell. (2020) 183:1367–82.e17. doi: 10.1016/j.cell.2020.10.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.043</ArticleId><ArticleId IdType="pmc">PMC7604136</ArticleId><ArticleId IdType="pubmed">33160446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang YF, Sun C, Zhuang Z, Yuan RY, Zheng Q, Li JP, et al. . Rapid development of SARS-coV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates. ACS Nano. (2021) 15:2738–52. doi: 10.1021/acsnano.0c08379</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c08379</ArticleId><ArticleId IdType="pubmed">33464829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Yuan RY, Xie C, Sun JF, Fang XY, Hu YS, et al. . Induction of broadly cross-reactive antibody responses to SARS-coV-2 variants by S1 nanoparticle vaccines. J Virol. (2022) 96:e0038322. doi: 10.1128/jvi.00383-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00383-22</ArticleId><ArticleId IdType="pmc">PMC9278117</ArticleId><ArticleId IdType="pubmed">35699445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Li Y, Xu FJ. Versatile functionalization of polysaccharides via polymer grafts: from design to biomedical applications. Acc Chem Res. (2017) 50:281–92. doi: 10.1021/acs.accounts.6b00477</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.6b00477</ArticleId><ArticleId IdType="pubmed">28068064</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Li J, Sun C, Chi H, Luo D, Wang R, et al. . Rational development of a polysaccharide-protein-conjugated nanoparticle vaccine against SARS-coV-2 variants and streptococcus pneumoniae. Adv Mater. (2022) 34:e2200443. doi: 10.1002/adma.202200443</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202200443</ArticleId><ArticleId IdType="pmc">PMC9073961</ArticleId><ArticleId IdType="pubmed">35332581</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yang L, Ou X, Li JY, Zi CT, Wang H, et al. . A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses. J Nanobiotechnology. (2022) 20:320. doi: 10.1186/s12951-022-01533-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01533-3</ArticleId><ArticleId IdType="pmc">PMC9281129</ArticleId><ArticleId IdType="pubmed">35836236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tursi NJ, Xu Z, Kulp DW, Weiner DB. Gene-encoded nanoparticle vaccine platforms for in vivo assembly of multimeric antigen to promote adaptive immunity. Wiley Interdiscip Rev Nanomed Nanobiotechnol. (2023) 15:e1880. doi: 10.1002/wnan.1880</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1880</ArticleId><ArticleId IdType="pmc">PMC10665986</ArticleId><ArticleId IdType="pubmed">36807845</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Wang L, Merriam JS, Shi W, Yang ES, Zhang Y, et al. . Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. NPJ Vaccines. (2023) 8:111. doi: 10.1038/s41541-023-00707-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00707-w</ArticleId><ArticleId IdType="pmc">PMC10409857</ArticleId><ArticleId IdType="pubmed">37553406</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrath KM, Liaw K, Wu Y, Zhu X, Walker SN, Xu Z, et al. . Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Rep. (2022) 38:110318. doi: 10.1016/j.celrep.2022.110318</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110318</ArticleId><ArticleId IdType="pmc">PMC8747942</ArticleId><ArticleId IdType="pubmed">35090597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, He L, Zhang H, Tian X, Bai Z, Sun L, et al. . The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct Target Ther. (2021) 6:340. doi: 10.1038/s41392-021-00750-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00750-w</ArticleId><ArticleId IdType="pmc">PMC8426336</ArticleId><ArticleId IdType="pubmed">34504054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Zhang X, Yuan Y, Deng X, Wu B, Xi Z, et al. . Development of receptor binding domain (RBD)-conjugated nanoparticle vaccines with broad neutralization against SARS-coV-2 delta and other variants. Adv Sci (Weinh). (2022) 9:e2105378. doi: 10.1002/advs.202105378</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202105378</ArticleId><ArticleId IdType="pmc">PMC9008796</ArticleId><ArticleId IdType="pubmed">35142444</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Zhang X, Chen R, Li Y, Wu B, Li R, et al. . A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. Cell Rep. (2022) 38:110256. doi: 10.1016/j.celrep.2021.110256</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110256</ArticleId><ArticleId IdType="pmc">PMC8695190</ArticleId><ArticleId IdType="pubmed">34990583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SA, Kim S, Kim GB, Goo J, Kim N, Lee Y, et al. . A multivalent vaccine based on ferritin nanocage elicits potent protective immune responses against SARS-coV-2 mutations. Int J Mol Sci. (2022) 23:6123. doi: 10.3390/ijms23116123</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23116123</ArticleId><ArticleId IdType="pmc">PMC9181758</ArticleId><ArticleId IdType="pubmed">35682801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang YF, Sun C, Sun J, Xie C, Zhuang Z, Xu HQ, et al. . Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nat Commun. (2022) 13:2674. doi: 10.1038/s41467-022-30222-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30222-w</ArticleId><ArticleId IdType="pmc">PMC9106700</ArticleId><ArticleId IdType="pubmed">35562337</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkkemper M, Veth TS, Brouwer PJM, Turner H, Poniman M, Burger JA, et al. . Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. iScience. (2022) 25:105649. doi: 10.1016/j.isci.2022.105649</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105649</ArticleId><ArticleId IdType="pmc">PMC9678814</ArticleId><ArticleId IdType="pubmed">36439375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AA, Gnanapragasam PNP, Lee YE, Hoffman PR, Ou S, Kakutani LM, et al. . Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science. (2021) 371:735–41. doi: 10.1101/2020.11.17.387092</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.17.387092</ArticleId><ArticleId IdType="pmc">PMC7928838</ArticleId><ArticleId IdType="pubmed">33436524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AA, van Doremalen N, Greaney AJ, Andersen H, Sharma A, Starr TN, et al. . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. (2022) 377:eabq0839. doi: 10.1126/science.abq0839</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq0839</ArticleId><ArticleId IdType="pmc">PMC9273039</ArticleId><ArticleId IdType="pubmed">35857620</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills RA, Tan TK, Cohen AA, Keeffe JR, Keeble AH, Gnanapragasam PNP, et al. . Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses. Nat Nanotechnol. (2024) 19:1216–23. doi: 10.1038/s41565-024-01655-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-024-01655-9</ArticleId><ArticleId IdType="pmc">PMC11329374</ArticleId><ArticleId IdType="pubmed">38710880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Zhang J, Xu Y, Chen M, Wang S, Lin G, et al. . Spatial engineering of heterotypic antigens on a DNA framework for the preparation of mosaic nanoparticle vaccines with enhanced immune activation against SARS-coV-2 variants. Angew Chem Int Ed Engl. (2024) 18:e202412294. doi: 10.1002/anie.202412294</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202412294</ArticleId><ArticleId IdType="pubmed">39030890</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater. (2013) 12:978–90. doi: 10.1038/nmat3775</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmat3775</ArticleId><ArticleId IdType="pmc">PMC3928825</ArticleId><ArticleId IdType="pubmed">24150416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, Li Z, Jaklenec A, Hu Q. Vaccine delivery systems toward lymph nodes. Adv Drug Delivery Rev. (2021) 179:113914. doi: 10.1016/j.addr.2021.113914</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.113914</ArticleId><ArticleId IdType="pmc">PMC9418125</ArticleId><ArticleId IdType="pubmed">34363861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. (2010) 10:787–96. doi: 10.1038/nri2868</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2868</ArticleId><ArticleId IdType="pubmed">20948547</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. (2008) 38:1404–13. doi: 10.1002/eji.200737984</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200737984</ArticleId><ArticleId IdType="pubmed">18389478</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JV, FG S. Dynamic intravital imaging of cell-cell interactions in the lymph node. J Allergy Clin Immunol. (2017) 139:12–20. doi: 10.1016/j.jaci.2016.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.11.008</ArticleId><ArticleId IdType="pubmed">28065277</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z, Que H, Chen L, Sun Q, Wei X. Nanomaterial-based drug delivery system targeting lymph nodes. Pharmaceutics. (2022) 14:1372. doi: 10.3390/pharmaceutics14071372</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14071372</ArticleId><ArticleId IdType="pmc">PMC9325242</ArticleId><ArticleId IdType="pubmed">35890268</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesters BA, van der Poel CE, Das A, Carroll MC. Antigen presentation to B cells. Trends Immunol. (2016) 37:844–54. doi: 10.1016/j.it.2016.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2016.10.003</ArticleId><ArticleId IdType="pubmed">27793570</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, Mebius RE, et al. . Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity. (2009) 30:264–76. doi: 10.1016/j.immuni.2008.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.12.014</ArticleId><ArticleId IdType="pmc">PMC2699624</ArticleId><ArticleId IdType="pubmed">19185517</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynoso GV, Weisberg AS, Shannon JP, McManus DT, Shores L, Americo JL, et al. . Lymph node conduits transport virions for rapid T cell activation. Nat Immunol. (2019) 20:602–12. doi: 10.1038/s41590-019-0342-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0342-0</ArticleId><ArticleId IdType="pmc">PMC6474694</ArticleId><ArticleId IdType="pubmed">30886418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerner MY, Torabi-Parizi P, Germain RN. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. Immunity. (2015) 42:172–85. doi: 10.1016/j.immuni.2014.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.12.024</ArticleId><ArticleId IdType="pubmed">25607462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal O, Lim HY, Gurevich I, Milo I, Shipony Z, Ng LG, et al. . DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J Exp Med. (2011) 208:2141–53. doi: 10.1084/jem.20102392</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20102392</ArticleId><ArticleId IdType="pmc">PMC3182054</ArticleId><ArticleId IdType="pubmed">21930767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulvmar MH, Werth K, Braun A, Kelay P, Hub E, Eller K, et al. . The atypical chemokine receptor CCRL1 shapes functional CCL21 gradients in lymph nodes. Nat Immunol. (2014) 15:623–30. doi: 10.1038/ni.2889</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2889</ArticleId><ArticleId IdType="pubmed">24813163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Jiang X, Qu M, Aninwene GE, 2nd, Jucaud V, Moon JJ, et al. . Engineering antiviral vaccines. ACS Nano. (2020) 14:12370–89. doi: 10.1021/acsnano.0c06109</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c06109</ArticleId><ArticleId IdType="pmc">PMC7534801</ArticleId><ArticleId IdType="pubmed">33001626</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. (2011) 29:621–63. doi: 10.1146/annurev-immunol-031210-101400</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101400</ArticleId><ArticleId IdType="pubmed">21314428</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Hernández S, Ugidos-Damboriena N, López-Sagaseta J. Self-assembling protein nanoparticles in the design of vaccines: 2022 update. Vaccines (Basel). (2022) 10:1447. doi: 10.3390/vaccines10091447</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10091447</ArticleId><ArticleId IdType="pmc">PMC9505534</ArticleId><ArticleId IdType="pubmed">36146525</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick AA, Palmer KE. Genetically engineered Tobacco mosaic virus as nanoparticle vaccines. Expert Rev Vaccines. (2008) 7:33–41. doi: 10.1586/14760584.7.1.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.7.1.33</ArticleId><ArticleId IdType="pubmed">18251692</ArticleId></ArticleIdList></Reference><Reference><Citation>Thérien A, Bédard M, Carignan D, Rioux G, Gauthier-Landry L, Laliberté-Gagné M, et al. . A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling. J Nanobiotechnol. (2017) 15:54. doi: 10.1186/s12951-017-0289-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-017-0289-y</ArticleId><ArticleId IdType="pmc">PMC5516373</ArticleId><ArticleId IdType="pubmed">28720097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>